CADTH Canadian Drug Expert Committee recommendation: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.) indication : chronic hepatitis C virus infection
The CADTH Canadian Drug Expert Committee (CDEC) recommends that sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX; Vosevi) be reimbursed for the treatment of adult patients with chronic hepatitis C virus (HCV) infection, without cirrhosis or with compensated cirrhosis, who have: genotype 1, 2, 3, 4,...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2018, January 2018
|
| Edition: | Version 1.0 |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX; Vosevi) be reimbursed for the treatment of adult patients with chronic hepatitis C virus (HCV) infection, without cirrhosis or with compensated cirrhosis, who have: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor; or genotype 1, 2, 3, or 4 infection and have been previously treated with an HCV regimen containing SOF without an NS5A inhibitor, if the following conditions are met. The patient is under the care of a physician with experience in the diagnosis and management of HCV infection. Drug plan cost for SOF/VEL/VOX should not exceed the drug plan cost for SOF/VEL. |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (7 pages) |